- Led the development, validation, and implementation of high-throughput screening assays for characterizing a microbial library (>120K isolates) with phenotypic data.- Collaborated with an interdisciplinary data science team to strategize and develop solutions for targeted screening of diverse microbes.

- Managed primary stem cell culture molecular and biochemical assays including IC50, permeability, cytotoxicity, ICC and fluorescence microscopy, and gene and protein expression analyses (ELISA, Luminex, BioMark).- Contributed to R&D projects developing novel assays to characterize proprietary primary stem cell culture platforms.

- Identified and classified design requirements and limitations during project feasibility phases- Assessed, optimized, and validated assay performance such as sensitivity, linearity, dynamic range, stability, interference, and method agreement following CLSI-FDA guidelines.- Collaborated with software and hardware engineers to develop and assess new technologies.- Supported the development of a SARS-nCoV-2 RT-PCR molecular assay and platform currently on the market.- Delivered presentations on current projects at company and team meetings.

- Successfully delivered a heparin monitoring project from R&D feasibility to product development.

- Contributed to multiple NIH grants to develop, optimize, and multiplex a variety of analytical assays.- Developed a chemiluminescence detection method with improved sensitivity over a fluorescence-based assay.- Demonstrated feasibility for detection of fentanyl in meconium and urine using a homogenous immunoassay on an automated microfluidic device; resulted in NIH grant award through the HEAL Initiative.- Established and evaluated a digital microfluidic GALT assay for a $183k NIH SBIR grant.- Produced protein C, ATIII, and factor VIII assays for a $215k Phase I NIH SBIR grant; $763k Phase II awarded.

- Constructed a clinical diagnostic hypoglycemia assay panel comprised of six biomarker tests utilizing functional enzymatic and immunoassays for Phase I of a fast-track NIH SBIR grant; $682k Phase II awarded.- Optimized assay designs and reagent formulations.- Designed and carried out focused studies to characterize assay performance across various analytical metrics.- Analyzed experimental results and provided protocols and oral presentations.- Collaborated with grant writers to author reports by providing technical information including graphs and statistics.

- Utilized techniques including PCR, ISH, IHC, DNA/RNA extraction and isolation, cell culture, and calcium imaging to identify, characterize, and elucidate pruritogenic & nociceptive pathways in genetically modified knockout mice.